|
1
|
Ozga M, Aghajanian C, Myers-Virtue S,
McDonnell G, Jhanwar S, Hichenberg S and Sulimanoff I: A systematic
review of ovarian cancer and fear of recurrence. Palliat Support
Care. 13:1–10. 2015. View Article : Google Scholar
|
|
2
|
Ye H, Karim AA and Loh XJ: Current
treatment options and drug delivery systems as potential
therapeutic agents for ovarian cancer: A review. Mater Sci Eng C
Mater Biol Appl. 45:609–619. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zafrakas M, Grimbizis G, Timologou A and
Tarlatzis BC: Endometriosis and ovarian cancer risk: A systematic
review of epidemiological studies. Front Surg. 1:142014. View Article : Google Scholar
|
|
4
|
Yoshida H, Teramae M, Yamauchi M, Fukuda
T, Yasui T, Sumi T, Honda K and Ishiko O: Association of copper
transporter expression with platinum resistance in epithelial
ovarian cancer. Anticancer Res. 33:1409–1414. 2013.PubMed/NCBI
|
|
5
|
Redman C, Duffy S and Dobson C: Improving
early detection of ovarian cancer. Practitioner. 255:27–30.
2011.PubMed/NCBI
|
|
6
|
Walters Haygood CL, Arend RC, Straughn JM
and Buchsbaum DJ: Ovarian cancer stem cells: Can targeted therapy
lead to improved progression-free survival? World J Stem Cells.
6:441–447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gallo D, Fruscella E, Ferlini C, Apollonio
P, Mancuso S and Scambia G: Preclinical in vivo activity of a
combination gemcitabine/liposomal doxorubicin against
cisplatin-resistant human ovarian cancer (A2780/CDDP). Int J
Gynecol Cancer. 16:222–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song T, Kim MK, Lee YY, Choi CH, Kim TJ,
Lee JW, Kim BG and Bae DS: Phase II study of ifosfamide and
cisplatin for the treatment of recurrent ovarian cancer. Cancer
Chemother Pharmacol. 72:653–660. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Musiani D, Hammond DE, Cirillo L, Erriquez
J, Olivero M, Clague MJ and Di Renzo MF: PIM2 kinase is induced by
cisplatin in ovarian cancer cells and limits drug efficacy. J
Proteome Res. 13:4970–4982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ziyan W and Yang L: MicroRNA-21 regulates
the sensitivity to cisplatin in a human osteosarcoma cell line. Ir
J Med Sci. 185:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lockhart AC, Sundaram S, Sarantopoulos J,
Mita MM, Wang-Gillam A, Moseley JL, Barber SL, Lane AR, Wack C,
Kassalow L, et al: Phase I dose-escalation study of cabazitaxel
administered in combination with cisplatin in patients with
advanced solid tumors. Invest New Drugs. 32:1236–1245. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Costello BA, Borad MJ, Qi Y, Kim JP,
Northfelt DW, Erlichman C and Alberts SR: Phase I trial of
everolimus, gemcitabine and cisplatin in patients with solid
tumors. Inves New Drugs. 32:710–716. 2014. View Article : Google Scholar
|
|
13
|
Joo WD, Lee JY, Kim JH, Yoo HJ, Roh HJ,
Park JY, Kim DY, Kim YM, Kim YT and Nam JH: Efficacy of taxane and
platinum-based chemotherapy guided by extreme drug resistance assay
in patients with epithelial ovarian cancer. J Gynecol Oncol.
20:96–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim HS, Kim TJ, Chung HH, Kim JW, Kim BG,
Park NH, Song YS, Bae DS and Kang SB: In vitro extreme drug
resistance assay to taxanes or platinum compounds for the
prediction of clinical outcomes in epithelial ovarian cancer: A
prospective cohort study. J Cancer Res Clin Oncol. 135:1513–1520.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karam AK, Chiang JW, Fung E, Nossov V and
Karlan BY: Extreme drug resistance assay results do not influence
survival in women with epithelial ovarian cancer. Gynecol Oncol.
114:246–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Wang J, Cai K, Jiang L, Zhou D,
Yang C, Chen J, Chen D and Dou J: Downregulation of gene MDR1 by
shRNA to reverse multidrug-resistance of ovarian cancer A2780
cells. J Cancer Res Ther. 8:226–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang S, Zhong Z, Wan J, Tan W, Wu G, Chen
M and Wang Y: Oridonin induces apoptosis, inhibits migration and
invasion on highly-metastatic human breast cancer cells. Am J Chin
Med. 41:177–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo
ZY, Xu MH, Wang ST, Jiang B, Liu F, et al: Oridonin induces
apoptosis and senescence in colorectal cancer cells by increasing
histone hyperacetylation and regulation of p16, p21, p27 and c-myc.
BMC Cancer. 10:6102010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi X, Zhang D, Xu X, Feng F, Ren G, Chu Q,
Zhang Q and Tian K: Oridonin nanosuspension was more effective than
free oridonin on G2/M cell cycle arrest and apoptosis in the human
pancreatic cancer PANC-1 cell line. Int J Nanomedicine.
7:1793–1804. 2012.PubMed/NCBI
|
|
20
|
Gao FH, Liu F, Wei W, Liu LB, Xu MH, Guo
ZY, Li W, Jiang B and Wu YL: Oridonin induces apoptosis and
senescence by increasing hydrogen peroxide and glutathione
depletion in colorectal cancer cells. Int J Mol Med. 29:649–655.
2012.PubMed/NCBI
|
|
21
|
Cui Q, Tashiro S, Onodera S, Minami M and
Ikejima T: Autophagy preceded apoptosis in oridonin-treated human
breast cancer MCF-7 cells. Biol Pharm Bull. 30:859–864. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang YY, Lv YF, Lu L and Cai L: Oridonin
inhibits mTOR signaling and the growth of lung cancer tumors.
Anticancer Drugs. 25:1192–1200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ding Y, Wang Y, Chen J, Hu Y, Cao Z, Ren P
and Zhang Y: P21 overexpression sensitizes osteosarcoma U2OS cells
to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Tumour
Biol. 35:3119–3123. 2014. View Article : Google Scholar
|
|
24
|
Hoshyar R, Bathaie SZ and Sadeghizadeh M:
Crocin triggers the apoptosis through increasing the Bax/Bcl-2
ratio and caspase activation in human gastric adenocarcinoma, AGS,
cells. DNA Cell Biol. 32:50–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu HF, Chie YJ, Yang MS, Lee CS, Fu JJ,
Yang JS, Tan TW, Wu SH, Ma YS, Ip SW and Chung JG: Apigenin induces
caspase-dependent apoptosis in human lung cancer A549 cells through
Bax- and Bcl-2-triggered mitochondrial pathway. Int J Oncol.
36:1477–1484. 2010.PubMed/NCBI
|
|
26
|
Huq F, Yu JQ, Beale P, Chan C, Arzuman L,
Nessa MU and Mazumder ME: Combinations of platinums and selected
phyto-chemicals as a means of overcoming resistance in ovarian
cancer. Anticancer Res. 34:541–545. 2014.PubMed/NCBI
|
|
27
|
Gamarra-Luques CD, Hapon MB, Goyeneche AA
and Telleria CM: Resistance to cisplatin and paclitaxel does not
affect the sensitivity of human ovarian cancer cells to
antipro-gestin-induced cytotoxicity. J Ovarian Res. 7:452014.
View Article : Google Scholar
|
